Retatrutide in Thailand

Buy retatrutide 30 mg and 40 mg research vials in Thailand

We stock retatrutide as a lyophilised research powder in two vial sizes, 30 mg and 40 mg, each sold singly or in 5- and 10-vial packs (current baht prices are shown in the size selector). Vials are stocked in Bangkok and dispatched the same day after manual confirmation, with free tracked delivery to Bangkok, Phuket, Chiang Mai and every other Thai province in about 2–3 days. Order by sending the cart message on WhatsApp, LINE or Telegram. Laboratory research use only; retatrutide is an investigational compound, not an approved medicine.

Retatrutide (developmental code LY3437943) is Eli Lilly's investigational triple-receptor agonist, a single peptide that activates the GLP-1, GIP, and glucagon receptors at once. This page covers the compound's identity and the peer-reviewed trial record. For its regulatory status, 2026 Phase 3 news and the checks that matter when sourcing it in Thailand, read the retatrutide Thailand guide; for how it differs from tirzepatide and semaglutide, see retatrutide vs tirzepatide vs semaglutide. Literature-reported study parameters are descriptive records rather than recommendations for use.

Quick facts

Product

Retatrutide (LY3437943)

Developer

Eli Lilly (investigational, not approved)

CAS number

2381089-83-2

Molecular weight

~4731 Da (peptide free base, reported)

Intended use

laboratory research use only

How retatrutide works

Retatrutide is a single acylated peptide engineered to switch on three metabolic receptors simultaneously. In vitro it shows balanced glucagon- and GLP-1-receptor activity with stronger GIP-receptor activity (Coskun et al., Cell Metab 2022, PMID 35985340). The GLP-1 and GIP arms are associated with glucose-dependent insulin secretion and reduced food intake; the glucagon arm is what sets it apart.

In obese mice, the same discovery paper attributed part of the body-weight reduction to glucagon-receptor-mediated increases in energy expenditure, added to GIP- and GLP-1-driven reductions in calorie intake (Coskun et al., 2022). That energy-expenditure finding is from the mouse work; the human trials below report body-weight, HbA1c and safety endpoints. In a phase 1b study in type 2 diabetes, pharmacokinetics were dose proportional with a half-life of approximately 6 days (Urva et al., Lancet 2022, PMID 36354040).

Key research findings

• In a phase 2 obesity trial (338 adults, 48 weeks), the 12 mg dose group showed a least-squares mean body-weight change of −24.2% versus −2.1% for placebo, with 83% of that group reaching at least 15% reduction (Jastreboff et al., NEJM 2023, PMID 37366315).
• In a phase 2 type 2 diabetes trial (281 adults), the 12 mg escalation group showed an HbA1c change of −2.02% at 24 weeks and a body-weight reduction of 16.94% at 36 weeks, versus −0.01% and 3.00% for placebo; the HbA1c reduction was significantly greater than the 1.5 mg dulaglutide comparator in the 8 mg slow-escalation and 12 mg groups (Rosenstock et al., Lancet 2023, PMID 37385280).
• In both phase 2 trials the most common adverse events were gastrointestinal and mostly mild to moderate; the obesity trial also reported dose-dependent heart-rate increases that peaked at 24 weeks (Jastreboff et al., 2023), and the diabetes trial recorded no severe hypoglycaemia and no deaths (Rosenstock et al., 2023).

Research applications

• Triple-receptor (GLP-1 / GIP / glucagon) pharmacology and additive receptor-engagement studies.
• Energy-expenditure and thermogenesis pathway investigations, contrasting intake- versus expenditure-driven effects.
• Hepatic lipid metabolism and metabolic-dysfunction-associated steatotic liver disease (MASLD/NASH) models.
• Comparative efficacy modelling against dual and single incretin agonists such as tirzepatide and semaglutide.
• Glycaemic-control and insulin-sensitivity studies in metabolic disease models.
• Substrate-utilisation and metabolic-flexibility research.

Study parameters reported in literature

Phase 2 trials escalated across that range in roughly 4-week steps, from 1 mg to 12 mg. These figures summarise what published trials reported and are provided for literature reference only, not as recommendations for use. To model concentrations and volumes for a study, use the peptide calculator.

Reconstitution & storage

Solvent

Confirm compatibility for this material; bacteriostatic water is a common laboratory diluent, not a validated solvent for every formulation

Mixing

Add solvent down the vial wall and swirl gently until dissolved; do not shake

Storage

Refrigerate at 2–8 °C after reconstitution, in common laboratory practice

Use within

No in-use stability data has been published for this material; set limits from a validated protocol

Freeze / light

Keep lyophilised powder frozen or refrigerated; protect from direct light; avoid repeated freeze–thaw

These are general laboratory handling conventions, not instructions for use or demonstrated stability of the supplied vial. In Thailand's heat and humidity, minimise time at room temperature.

Selected research

• LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept — Cell Metabolism, 2022 (PMID 35985340).
• LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b multiple-ascending dose trial — The Lancet, 2022 (PMID 36354040).
• Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial — New England Journal of Medicine, 2023 (PMID 37366315).
• Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial — The Lancet, 2023 (PMID 37385280).
• Further indexed literature via PubMed search for retatrutide.

Related compounds

• Semaglutide — single GLP-1 agonist; the baseline of the incretin family and a common comparison point in metabolic research. Tirzepatide (dual GLP-1 / GIP) sits between the two but is not currently in our catalog.
• PT-141 — bremelanotide, an agonist at MC4R. That hypothalamic receptor sits in the brain's own energy-balance circuitry, so melanocortin compounds are a separate, central route into questions that incretin research approaches through gut-hormone receptors.
• Bacteriostatic water — the standard diluent used to reconstitute lyophilised research peptides.

See also: retatrutide vs semaglutide vs tirzepatide, the retatrutide Thailand research guide, and more incretin-receptor compounds.